Chemoprevention of chemically induced skin tumorigenesis by ligand activation of peroxisome proliferator-activated receptor-β/δ and inhibition of cyclooxygenase 2

Molecular Cancer Therapeutics

Volumn 9, Issue 12, 2010, Pages 3267-3277

  Zhu, Bokai ^a,b   Bai, Robert ^a   Kennett, Mary J ^a   Kang, Boo Hyon ^c   Gonzalez, Frank J ^d   Peters, Jeffrey M ^a,b,e  

^a Department of Veterinary and Biomedical Sciences   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c Preclinical Research Center   (South Korea)

^d NATIONAL CANCER INSTITUTE   (United States)

^e PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; CYCLOOXYGENASE 2; NIMESULIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; INFLAMMATION; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN CARCINOGENESIS;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CHEMOPREVENTION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; INFLAMMATION; LIGANDS; MICE; PPAR DELTA; PPAR-BETA; SKIN NEOPLASMS; SULFONAMIDES; THIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 78650479942     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0820     Document Type: Article

References (35)

1. Smith WL. The eicosanoids and their biochemical mechanisms of action. Biochem J 1989;259:315-24.
2. Hla T, Ristimaki A, Appleby S, Barriocanal JG. Cyclooxygenase gene expression in inflammation and angiogenesis. Ann NY Acad Sci 1993;696:197-204.
3. Tiano HF, Loftin CD, Akunda J, Lee CA , Spalding J , Sessoms A , et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 2002;62:3395-401.
4. Fischer SM, Conti CJ, Viner J, Aldaz CM, Lubet RA. Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice. Carcinogenesis 2003;24: 945-52.
5. Pentland AP, Schoggins JW, Scott GA, Khan KN, Han R. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 1999;20:1939-44.
6. Kim DJ, Prabhu KS, Gonzalez FJ, Peters JM. Inhibition of chemicallyinduced skin carcinogenicity by sulindac is independent of peroxisome proliferator-activated receptor-b/d (PPARb/d). Carcinogenesis 2006;27:1105-12.
7. Bility MT, Zhu B, Kang BH, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-b/d and inhibition of cyclooxygenase-2 enhances inhibition of skin tumorigenesis. Toxicol Sci 2010;113:27-36.
8. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation. Pharmacol Ther 2004;103:147-66.
9. Tober KL, Thomas-Ahner JM, Kusewitt DF, Oberyszyn TM. Effects of UVB on E prostanoid receptor expression in murine skin. J Invest Dermatol 2007;127:214-21.
10. Sung YM, He G, Fischer SM. Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. Cancer Res 2005;65:9304-11.
11. Burdick AD, Kim DJ, Peraza MA, Gonzalez FJ, Peters JM. The role of peroxisome proliferator-activated receptor-b/d in epithelial cell growth and differentiation. Cell Signal 2006;18:9-20.
12. Lee CH, Olson P, Evans RM. Minireview: Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003;144:2201-7.
13. Peraza MA, Burdick AD, Marin HE, Gonzalez FJ, Peters JM. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol Sci 2006;90:269-95.
14. Peters JM, Gonzalez FJ. Sorting out the functional role(s) of peroxisome proliferator-activated receptor-b/d (PPARb/d) in cell proliferation and cancer. Biochim Biophys Acta 2009;1796:230-41.
15. Peters JM, Hollingshead HE, Gonzalez FJ. Role of peroxisome-proliferator- activated receptor b/d (PPARb/d) in gastrointestinal tract function and disease. Clin Sci (Lond) 2008;115:107-27.
16. Lalloyer F, Staels B. Fibrates, glitazones, and peroxisome proliferator- activated receptors. Arterioscler Thromb Vasc Biol 2010;30: 894-9.
17. Girroir EE, Hollingshead HE, He P, Zhu B, Perdew GH, Peters JM. Quantitative expression patterns of peroxisome proliferator-activated receptor-b/d (PPARb/d) protein in mice. Biochem Biophys Res Commun 2008;371:456-61.
18. Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, Rieusset J, et al. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)a and PPARb mutant mice. J Cell Biol 2001;154:799-814.
19. Peters JM, Lee SST, Li W, Ward JM, Gavrilova O, Everett C, et al. Growth, adipose, brain and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor b/d. Mol Cell Biol 2000;20:5119-28.
20. Kim DJ, Akiyama TE, Harman FS, Burns AM , ShanW, Ward JM , et al. Peroxisome proliferator-activated receptor b (d)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J Biol Chem 2004;279:23719-27.
21. Bility MT, Devlin-Durante MK, Blazanin N, Glick AB, Ward JM, Kang BH, et al. Ligand activation of peroxisome proliferator-activated receptor-b/d (PPARb/d) inhibits chemically-induced skin tumorigenesis. Carcinogenesis 2008;29:2406-14.
22. Foreman JE, Sorg JM, McGinnis KS, Rigas B , Williams JL, Clapper ML, et al. Regulation of peroxisome proliferator-activated receptorb/ d by the APC/b-CATENIN pathway and nonsteroidal antiinflammatory drugs. Mol Carcinog 2009;48:942-52.
23. Bachmanov AA, Reed DR, Beauchamp GK, Tordoff MG. Food intake, water intake, and drinking spout side preference of 28 mouse strains. Behav Genet 2002;32:435-43.
24. Dlugosz AA, Glick AB, Tennenbaum T, Weinberg WC, Yuspa SH. Isolation and utilization of epidermal keratinocytes for oncogene research. Methods Enzymol 1995;254:3-20.
25. Palkar PS, Borland MG, Naruhn S, Ferry CH, Lee C, Sk UH, et al. Cellular and pharmacological selectivity of the PPARb/d antagonist GSK3787. Mol Pharmacol 2010;78:419-30.
26. Murray IA, Krishnegowda G, Dinatale BC, Flaveny C, Chiaro C, Lin JM, et al. Development of a selective modulator of aryl hydrocarbon (Ah) receptor activity that exhibit anti-inflammatory properties. Chem Res Toxicol 2010;23:955-66.
27. Shan W, Palkar PS, Murray IA, McDevitt EI, Kennett MJ, Kang BH, et al. Ligand activation of peroxisome proliferator-activated receptor b/d (PPARb/d) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. Toxicol Sci 2008;105:418-28.
28. Kim DJ, Bility MT, Billin AN, Willson TM, Gonzalez FJ, Peters JM. PPARb/d selectively induces differentiation and inhibits cell proliferation. Cell Death Differ 2006;13:53-60.
29. Schmuth M, Haqq CM, Cairns WJ, Holder JC, Dorsam S, Chang S, et al. Peroxisome proliferator-activated receptor (PPAR)-b/d stimulates differentiation and lipid accumulation in keratinocytes. J Invest Dermatol 2004;122:971-83.
30. Akunda JK, Lao HC, Lee CA, Sessoms AR, Slade RM, Langenbach R. Genetic deficiency or pharmacological inhibition of cyclooxygenase-1 or -2 induces mouse keratinocyte differentiation in vitro and in vivo. FASEB J 2004;18:185-7.
31. Westergaard M, Henningsen J, Svendsen ML, Johansen C, Jensen UB, Schrder HD, et al. Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J Invest Dermatol 2001;116:702-12.
32. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
33. Kilgore KS, Billin AN. PPARb/d ligands as modulators of the inflammatory response. Curr Opin Investig Drugs 2008;9: 463-9.
34. Renard JF, Julemont F, de Leval X, Pirotte B. The use of nimesulide and its analogues in cancer chemoprevention. Anticancer Agents Med Chem 2006;6:233-7.
35. Kim DJ, Murray IA, Burns AM, Gonzalez FJ, Perdew GH, Peters JM. Peroxisome proliferator-activated receptor-b/d (PPARb/d) inhibits epidermal cell proliferation by down-regulation of kinase activity. J Biol Chem 2005;280:9519-27.